Modeling of hepatic elimination and organ distribution kinetics with the extended convection-dispersion model

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 27, Issue 4, 1999, Pages 343-382

  Roberts, Michael S ^a   Anissimov, Yuri G ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Convection dispersion model; Extended convection dispersion model; Hepatic disposition; Hepatic elimination; Interconnecting sinusoids; Inverse Gaussian distribution; Secondary vascular compartment

Indexed keywords

CARBON 14; PALMITIC ACID; SUCROSE; TELLURIUM; TRITIUM;

ANIMAL TISSUE; ARTICLE; CLEARANCE; CONCENTRATION (PARAMETERS); DISPERSION; KINETICS; LIQUID SCINTILLATION COUNTING; LIVER; LIVER BLOOD FLOW; MODEL; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; RAT; THERMODYNAMICS;

EID: 0033500591     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020992421184     Document Type: Article

References (52)

1. 1. M. Rowland, L. Z. Benet, and G. G. Graham. Clearance concepts in pharmacokinetics. J. Pharmacokin. Biopharm. 1:123-136 (1973).
2. 2. K. Winkler, L. Bass, S. Keiding, and N. Tygstrup. The effect of hepatic perfusion on the assessment of kinetic constants in regulation of hepatic metabolism. In F. Lundquist and N. Tygstrup (eds.), A. Benzon Symposium VI, Munksgaard, Copenhagen, 1974, pp. 797-807.
3. 3. J. Burggraaf, H. C. Schoemaker, and A. F. Cohen. Assessment of changes in liver blood flow after food intake-comparison of ICG clearance and echo-Doppler. Br. J. Clin. Pharmacol. 42:499-502 (1996).
4. 4. J. Burggraaf, R. C. Schoemaker, J. M. Kroon, and A. F. Cohen. The influence of nifedipine and captopril on liver blood flow in healthy subjects. Br. J. Clin. Pharmacol. 45:447-451 (1998).
5. 5. G. R. Wilkinson and D. G. Shand. Commentary: a physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18:377-390 (1975).
6. 6. M. S. Roberts and M. Rowland. Hepatic elimination - dispersion model. J. Pharm. Sci. 74:585-587 (1985).
7. 7. M. S. Roberts and M. Rowland. A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J. Pharmacokin. Biopharm. 14:227-260 (1986).
8. 8. M. S. Roberts, J. D. Donaldson, and M. Rowland. Models of hepatic elimination: comparison of stochastic models to describe residence time distributions and to predict the influence of drug distribution, enzyme heterogeneity and systemic recycling on hepatic elimination. J. Pharmacokin. Biopharm. 16:41-83 (1988).
9. 9. M. S. Roberts and M. Rowland. A dispersion model of hepatic elimination: 2. Steady-state considerations. Influence of blood flow, protein binding and hepatocellular enzymatic activity. J. Pharmacokin. Biopharm. 14:261-288 (1986).
10. 10. M. S. Roberts and M. Rowland. A dispersion model of hepatic elimination: 3. Application to metabolite formation and elimination kinetics. J. Pharmacokin. Biopharm. 14:289-307 (1986).
11. 11. M. S. Roberts and M. Rowland. Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: Analysis with a dispersion model. J. Pharm. Pharmacol. 38:117-181 (1986).
12. 12. M. S. Roberts, J. D. Donaldson, and D. Jackett. Availability predictions by hepatic elimination models for Michaelis-Menten kinetics. J. Pharmacokin. Biopharm. 17:687-719 (1989).
13. 13. L. Bass, M. S. Roberts, and P. J. Robinson. On the relation between extended forms of the sinusoidal perfusion and of the convection-dispersion models of hepatic elimination. J. Theoret. Biol. 126:457-482 (1987).
14. 14. P. J. Robinson, L. Bass, S. M. Pond, M. S. Roberts, and J. G. Wagner. Clinical applicability of current pharmacokinetic models: splanchnic elimination of 5-fluorouracil in cancer patients. J. Pharmacokin. Biopharm. 16:229-249 (1988).
15. 15. T. Iwatsubo, H. Suzuki, N. Shimada, K. Chiba, T. Ishizaki, C. E. Green, C. A. Tyson, T. Yokoi, T. Kamataki, and Y. Sugiyama. Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. J. Pharmacol. Exp. Ther. 282:909-919 (1997).
16. 16. Y. Yano, K. Yamaoka, Y. Aoyama, and H. Tanaka. Two-compartment dispersion model for analysis of organ perfusion system of drugs by fast inverse Laplace transform (FILT). J. Pharmacokin. Biopharm. 17:179-202 (1989).
17. 17. A. M. Evans, Z. Hussein, and M. Rowland. A two-compartment dispersion model describes the hepatic outflow profile of diclofenac in the presence of its binding protein. J. Pharm. Pharmacol. 43:709-714 (1991).
18. 18. M. S. Roberts, S. Fraser, A. Wagner, and L. McLeod. Residence time distributions of solutes in the perfused rat liver using a dispersion model of hepatic elimination: 1. Effect of changes in perfusate flow and albumin concentration on sucrose and taurocholate. J. Pharmacokin. Biopharm. 18:209-234 (1990).
19. 19. L. N. Ballinger, S. E. Cross, and M. S. Roberts. Availability and mean transit times of phenol and its metabolites in the isolated perfused rat liver: normal and retrograde studies using tracer concentrations of phenol. J. Pharm. Pharmacol. 47:949-956 (1995).
20. 20. B. A. Luxon and R. A. Weisiger. Extending the multiple indicator dilution method to include slow intracellular diffusion. Math. Biosci. 113:211-230 (1993).
21. 21. L. P. Rivory, M. S. Roberts, and S. M. Pond. Axial tissue diffusion can account for the disparity between current models of hepatic elimination for lipophilic drugs. J. Pharmacokin. Biopharm. 20:19-61 (1992).
22. 22. G. D. Mellick, Y. G. Anissimov, A. J. Bracken, and M. S. Roberts. Metabolite mean transit times in the liver as predicted by various models of hepatic elimination. J. Pharmacokin. Biopharm. 25:477-505 (1997).
23. 23. D. Y. Hung, G. D. Mellick, Y. G. Anissimov, M. Weiss, and M. S. Roberts. Hepatic structure-pharmacokinetic relationships: the hepatic disposition and metabolite kinetics of a homologous series of O-acyl derivatives of salicylic acid. Br. J. Pharmacol. 124:1475-1483 (1998).
24. 24. D. Y. Hung, G. D. Mellick, Y. G. Anissimov, M. Weiss, and M. S. Roberts. Hepatic disposition and metabolite kinetics of a homologous series of diflunisal esters. J. Pharm. Sci. 87:943-951 (1998).
25. 25. C. H. Chou and M. Rowland. Effect of altered tissue binding on the disposition of barbital in the isolated perfused rat liver: application of the axial dispersion model. J. Pharm. Sci. 86:1310-1314 (1997).
26. 26. M. Weiss, C. Stedtler, and M. S. Roberts. On the validity of the dispersion model of hepatic drug elimination when intravascular transit time densities are long-tailed. Bull. Math. Biol. 59:911-929 (1997).
27. 27. M. Weiss and M. S. Roberts. Tissue distribution kinetics as determinant of transit time dispersion of drugs in organs: application of a stochastic model to the rat hindlimb. J. Pharmacokin. Biopharm. 24:173-196 (1996).
28. 28. R. E. Oliver, A. C. Heatherington, A. F. Jones, and M. Rowland. A physiologically based pharmacokinetic model incorporating dispersion principles to describe solute distribution in the perfused rat hindlimb preparation. J. Pharmacokin. Biopharm. 25:389-412 (1997).
29. 29. A. J. Schwab, W. Geng, and K. S. Pang. Application of the dispersion model for description of the outflow dilution profiles of noneliminated reference indicators in rat liver perfusion studies. J. Pharmacokin. Biopharm. 26:163-181 (1998).
30. 30. C. A. Goresky, G. C. Bach, and B. E. Nadeau. On the uptake of materials by the intact liver. The transport and net removal of galactose. J. Clin. Invest. 52:991-1009 (1973).
31. 31. B. A. Luxon, D. C. Holly, M. T. Milliano, and R. A. Weisiger. Sex differences in multiple steps in hepatic transport of palmitate support a balanced uptake mechanism. Am. J. Physiol. 274:G51-61 (1998).
32. 32. A. Kreft and A. Zuber. On the physical meaning of the dispersion equation and its solutions for different initial and boundary conditions. Chem. Eng. Sci. 33:1471-1480 (1978).
33. 33. G. F. Froment and K. B. Bischoff. Chemical Reactor Analysis and Design, John Wiley, New York, 1989.
34. 34. P. V. Danckwerts. Continuous flow systems: distribution of residence times. Chem. Eng. Sci. 2:1-13 (1953).
35. 35. Y. S. Choe, I. S. Kang, and K. S. Chang. A study of the dynamic behaviour of the dispersion-type tubular reactor models. Korean J. Chem. Eng. 15:95-98 (1998).
36. 36. M. T. van Genuchten and J. C. Parker. Boundary conditions for displacement experiments through short laboratory soil columns. Soil Sci. Soc. Am. J. 48:703-708 (1984).
37. 37. R. D. Purves. Accuracy of numerical inversion of Laplace transforms for pharmacokinetic parameter estimation. J. Pharm. Sci. 84:71-74 (1995).
38. 38. A. Koo, I. Y. Liang, and K. K. Cheng. The terminal hepatic microcirculation in the rat. Quart. J. Exp. Physiol. Cogn. Med. Sci. 60:261-266 (1975).
39. 39. W. Geng, A. J. Schwab, T. Horie, C. A. Goresky, and K. S. Pang. Hepatic uptake of bromosulfophthalein-glutathione in perfused Eisai hyperbilirubinemic mutant rat liver: a multiple-indicator dilution study. J. Pharmacol. Exp. Ther. 284:480-492 (1998).
40. 40. A. J. Schwab, F. D. Barker, C. A. Goresky, and K. S. Pang. Transfer of enalaprilat across rat liver cell membranes is barrier limited. Am. J. Physiol. 258:G461-475 (1990).
41. 41. K. S. Pang, and M. Rowland. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokin. Biopharm. 5:625-653 (1977).
42. 42. A. W. Wolkoff, C. A. Goresky, J. Sellin, Z. Gatmaitan, and I. M. Arias. Role of ligandin in transfer of bilirubin from plasma into liver. Am. J. Physiol. 236:E638-648 (1979).
43. 43. Z. Hussein, A. J. McLachlan, and M. Rowland. Distribution kinetics of salicylic acid in the isolated perfused rat liver assessed using moment analysis and the two-compartment axial dispersion model. Pharm. Res. 11:1337-1345 (1994).
44. 44. C. H. Chou, A. M. Evans, G. Fornasini, and M. Rowland. Relationship between lipophilicity and hepatic dispersion and distribution for a homologous series of barbiturates in the isolated perfused in situ rat liver. Drug Metab. Dispos. 21:933-938 (1993).
45. 45. A. M. Evans, Z. Hussein, and M. Rowland. Influence of albumin on the distribution and elimination kinetics of diclofenac in the isolated perfused rat liver: analysis by the impulse-response technique and the dispersion model. J. Pharm. Sci. 82:421-428 (1993).
46. 46. J. M. Diaz-Garcia, A. M. Evans, and M. Rowland. Application of the axial dispersion model of hepatic drug elimination to the kinetics of diazepam in the isolated perfused rat liver. J. Pharmacokin. Biopharm. 20:171-193 (1992).
47. 47. R. G. Tirona, A. J. Schwab, W. Geng, and K. S. Pang. Hepatic clearance models: comparison of the dispersion and Goresky models in outflow profiles from multiple indicator dilution rat liver studies. Drug Metab. Dispos. 26:465-475 (1998).
48. 48. J.-Y. Parlange, J. L. Starr, M. T. van Genuchten, D. A. Barry, and J. C. Parker. Exit condition for miscible displacement experiments. Soil Sci. 153:165-171 (1992).
49. 49. J. C. Parker. Analysis of solute transport in column tracer studies. Soil Sci. Soc. Am. J. 48:719-724 (1984).
50. 50. Y. G. Anissimov, A. J. Bracken, and M. S. Roberts. Interconnected-tubes model of hepatic elimination. J. Theoret. Biol. 188:89-101 (1997).
51. 51. C. A. Goresky. A linear method for determining liver sinusoidal and extravascular volumes. Am. J. Physiol. 204:626-640 (1963).
52. 52. C. A. Goresky. Kinetic interpretation of hepatic multiple-indicator dilution studies. Am. J. Physiol. 245:G1-12 (1983).